Evaluation of adverse events focusing on infection associated with infliximab originator and biosimilar using a spontaneous reporting system database

BACKGROUND: Infliximab (IFX) has changed the management of many life-threatening immune-mediated diseases. The high cost of IFX and its patent expiry have led to pharmaceutical companies developing a biosimilar; however, its safety profile remains unknown in the real world. The purpose of this study...

Descripción completa

Detalles Bibliográficos
Autores principales: Niinomi, Iku, Hosohata, Keiko, Mori, Yasuhiro, Yamaguchi, Yuki, Wakabayashi, Tomohito, Uchida, Mayako, Iwanaga, Kazunori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6781388/
https://www.ncbi.nlm.nih.gov/pubmed/31608149
http://dx.doi.org/10.1186/s40780-019-0149-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6781388/
https://www.ncbi.nlm.nih.gov/pubmed/31608149
http://dx.doi.org/10.1186/s40780-019-0149-z

Ejemplares similares